Metalon

Quick links to important sections

Metalon

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Metalon

Quick Facts

Property Description
Active Ingredient Metoclopramide (as Hydrochloride)
Form Tablet, Oral Solution, Injectable Solution
Pharmacological Class Prokinetic Agent and Antiemetic Agent
General Purpose Relieving nausea/vomiting and stomach motility issues
Origin Synthetic compound (substituted benzamide)

What Type of Medicine is Metalon?

Metalon is a synthetic prescription drug classified as both a Prokinetic Agent and an Antiemetic Agent. Its pharmacological identity is defined by the active component, Metoclopramide (typically present as the hydrochloride salt), making it a single-ingredient therapy. This compound belongs to the substituted benzamide class, a chemical structure that allows it to modulate neural and muscular activity within the gastrointestinal tract. Pharmacological studies confirm its broad clinical recognition for managing issues related to gastric mobility and suppressing the vomiting reflex.

The Dual Purpose of a Prokinetic Antiemetic

The general purpose of Metalon is to alleviate symptoms related to impaired digestive tract movement and feelings of nausea. Metalon functions by both physically stimulating the upper gastrointestinal tract muscles and suppressing signals that trigger vomiting. This dual action is clinically recognized for accelerating the emptying of stomach contents and increasing the tone of the lower esophageal sphincter, which addresses gastric distress and the urge to vomit. Its use scenario often involves relieving the unpleasant sensations of stomach fullness or bloating that occur when the stomach is slow to empty.

Forms and Administration Type

Metalon is manufactured in diverse pharmaceutical presentations to suit different patient needs, including solid tablets, an oral solution for liquid dosing, and a sterile injectable solution. This means the active substance is suited for administration via the oral, intravenous, and intramuscular routes. The availability of injectable forms is essential for situations where a patient cannot safely take oral medication, ensuring that systemic delivery can be achieved, which is a key differentiator from oral-only antiemetics.

Regulatory References

  1. Metoclopramide: MedlinePlus Drug Information

What side effects are possible with Metalon?

Possible Side Effects and Safety Information

The officially documented safety profile of Metalon (Metoclopramide) is structured around two primary concerns: neurological function and duration of exposure. Adverse reactions are classified according to frequency and affect several System-Organ Classes.

Frequency-Classified Adverse Reactions

Frequency Category Examples of Listed Effects
Very Common Somnolence (Drowsiness)
Common Diarrhea, Asthenia (Fatigue), Depression, Hypotension, Acute Extrapyramidal Disorders
Rare Convulsion/Seizures, Confusion, Galactorrhea

Serious Adverse Reactions and Duration Constraints

The most serious regulatory concern is Tardive Dyskinesia (TD), a potentially irreversible movement disorder. The risk of TD is directly related to the duration of treatment and cumulative dose. For this reason, regulatory documents strictly advise against using Metalon for longer than 12 weeks.

Other serious adverse reactions include Neuroleptic Malignant Syndrome (NMS), a rare but life-threatening reaction, and acute Extrapyramidal Symptoms (EPS), such as involuntary muscle spasms, which typically occur early in treatment, often at higher doses.

Population-Specific Safety Considerations

Official labels detail safety constraints for specific groups. Older adults have an increased risk of developing Tardive Dyskinesia. Children under one year of age are contraindicated due to heightened risk of neurological disorders. For patients with renal or severe hepatic impairment, a dose reduction is formally recommended due to reduced drug clearance and potential accumulation.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation describes the signs and symptoms of Metalon (Metoclopramide) overdose, which are primarily related to effects on the Central Nervous System (CNS) and motor control.

Documented Manifestations and Severe Outcomes

Classification Manifestation/Outcome
CNS Effects Drowsiness, confusion, disorientation, lethargy, and seizures (convulsions).
Movement Disorders Extrapyramidal Reactions (EPS), including acute dystonic reactions and uncontrollable movements.
Life-Threatening Risk Methemoglobinemia, a blood condition, which is a particular risk for neonates and infants following overdose.

Required Emergency Actions

If overdose is suspected or if severe symptoms such as collapse, difficulty breathing, seizures, or unresponsiveness occur, immediate action is mandated by government guidance. Emergency services must be called at once, and the Poison Control Helpline should be contacted.

Supportive Management

Treatment is officially defined as symptomatic and supportive. While no specific antidote for Metalon is known, the official labeling documents the use of certain anticholinergic or antiparkinson drugs to manage the resulting EPS. Furthermore, methylene blue is described for reversing methemoglobinemia. Dialysis is generally not considered an effective removal method for the drug.

Population-Specific Notes

Regulatory information notes that neonates and infants are at a heightened risk for methemoglobinemia. Pediatric patients and adults under 30 years old show greater susceptibility to extrapyramidal reactions.

Therapeutic Uses of Metalon

Therapeutic Indications

Metalon is primarily indicated for the management of gastrointestinal motility disorders and the prevention of nausea and vomiting associated with various clinical conditions. It belongs to a class of medications known as prokinetics and antiemetics, working to facilitate the movement of food through the digestive tract.

Gastrointestinal Motility Disorders

The medication is frequently utilized to treat symptoms of gastroparesis, a condition where the stomach empties too slowly. This can occur as a complication of diabetes or following certain surgical procedures. By stimulating the muscles of the gastrointestinal tract, the medication helps alleviate symptoms such as:

  • Early satiety (feeling full shortly after starting a meal)
  • Persistent nausea
  • Abdominal bloating and discomfort
  • Persistent heartburn or acid reflux that has not responded to standard treatments

Prevention of Nausea and Vomiting

Metalon is effective in managing emesis (vomiting) triggered by different stimuli. Its primary uses in this area include:

  • Postoperative Recovery: Management of nausea and vomiting that may occur following general anesthesia and surgery.
  • Medical Procedures: Prevention of nausea during diagnostic procedures, such as small bowel intubation, where it helps facilitate the passage of medical instruments into the intestine.
  • General Antiemetic Use: Relief from nausea associated with acute migraines or other temporary gastrointestinal disturbances.

Mechanism of Action and Benefits

The therapeutic benefits of Metalon are derived from its dual action in the body. It acts centrally by blocking dopamine receptors in the brain's chemoreceptor trigger zone, which suppresses the urge to vomit. Locally, it enhances the response to acetylcholine in the upper digestive tract, which increases the tone and amplitude of gastric contractions and relaxes the pyloric sphincter.

The main benefits of this treatment include:

  • Improved Gastric Emptying: By accelerating the transit of contents from the stomach to the small intestine, it reduces the risk of acid reflux and esophageal irritation.
  • Symptomatic Relief: Provides a significant reduction in the frequency and severity of nausea episodes.
  • Enhanced Digestive Comfort: Helps restore a more natural rhythm to the digestive process for individuals with chronic motility issues.

Eligibility and Restrictions for Use

Metalon (Metoclopramide) eligibility is strictly defined by regulatory documents, distinguishing between populations allowed standard use, those requiring conditional use, and those who are absolutely contraindicated.

Contraindicated Populations and Conditions

Use of Metalon is prohibited for individuals with Gastrointestinal hemorrhage, mechanical obstruction, or perforation. It is also contraindicated in patients with Pheochromocytoma, Epilepsy, or Parkinson's disease, as well as those with a history of Tardive Dyskinesia or specific blood disorders like methaemoglobinaemia.

Age and Physiological Restrictions

Metalon is contraindicated in children under 1 year of age. Use in pediatric patients (1–18 years) is heavily restricted and often limited to specific, second-line antiemetic indications. Use is not recommended for women who are lactating due to drug excretion into breast milk. Use during pregnancy is conditional, requiring medical assessment.

Conditional Use Requirements

Patients with moderate to severe Renal Impairment or Severe Hepatic Impairment are eligible only if a dose reduction is formally implemented. Similarly, older adults may require a dose adjustment based on organ function and increased sensitivity to adverse reactions, as specified in official prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents classify Metalon’s (Metoclopramide) interaction profile based on its metabolic clearance and pharmacologic activity.

Documented Pharmacokinetic and Pharmacodynamic Effects

Category Interaction Outcome as per Regulatory Label
Dopaminergic Agonists (e.g., Levodopa) Mutual antagonism of therapeutic effect. Co-administration is formally prohibited.
Strong CYP2D6 Inhibitors Increased Metalon systemic exposure due to reduced clearance, raising the risk of dose-related adverse reactions.
CNS Depressants (e.g., Alcohol) Potentiated sedative effect; increased risk of central nervous system depression.
Neuroleptics/Antipsychotics Additive pharmacodynamic risk for the development of Extrapyramidal Symptoms (EPS).

Effect on Other Medicines and Restrictions

Metalon alters the systemic exposure of certain co-administered drugs due to accelerated gastric emptying. For example, it decreases the absorption of Digoxin and increases the bioavailability of Cyclosporine. The absorption of drugs primarily absorbed from the stomach, such as Acetaminophen, is also accelerated. The regulatory label advises against combining Metalon with MAO Inhibitors due to a potential risk of hypertension. In cases of Renal Impairment or in individuals identified as CYP2D6 Poor Metabolizers, Metalon’s clearance is reduced, which can lead to drug accumulation.

Mechanism of Action

How Metalon Works

Metalon modulates specific signaling dynamics within key biological systems by influencing core mechanisms underlying increased or altered physiological processes.


Targeted Receptor and Enzyme Modulation

Metalon exerts its primary action by selective binding to defined receptor systems and associated intracellular enzymes. By acting as a highly selective modulator, the compound initiates or suppresses initial signaling sequences. This interaction adjusts the baseline excitability of cells and modifies the transduction of excessive mediator activity across the cell membrane.


Modulating Signal Transduction Cascades

Following primary binding, Metalon influences molecular cascades by modifying early molecular steps and altering the flow of secondary messengers. The compound engages mechanisms that influence feedback regulation within the affected pathways. This modification supports a more regulated state within targeted pathways, ultimately contributing to the resultant output signal of those pathways.


Adjusting Central and Peripheral Pathway Balance

Metalon's mechanism acts within systems where targeted pathway adjustment is required for regulatory influence. It helps regulate processes driven by distinct signaling patterns across both central and peripheral pathways. This targeted interference modulates the intensity of increased physiological responses, influencing the regulatory balance within systems characterized by heightened signaling.

Dosage and Administration Information

How to Use Metalon

The administration of Metalon follows established parameters regarding routes, frequency, dosing limits, and contextual requirements. The medication is prepared in forms suitable for Oral administration (tablets and solutions) and Parenteral administration (Intravenous or Intramuscular injection).

Official Usage Patterns

The typical pattern for continuous oral use is four times daily (q.i.d.). To achieve the intended action, oral doses are taken on an empty stomach, specifically 30 minutes before each meal and the final dose at bedtime. The standard adult dose unit is often 10 mg, with the total daily dose capped to a maximum of 40 mg to 60 mg, depending on the indication.

Continuous use of Metalon is generally structured as a time-limited course and should not exceed 12 weeks in duration for non-acute conditions. For acute scenarios, such as when the injectable solution is used, the intravenous dose is administered slowly over a minimum period of one to two minutes.

Population-Specific Dosing

Dose adjustments are necessary for certain populations. Patients with impaired renal function (kidney issues) or significant hepatic impairment (liver issues) receive a reduced maintenance dose. For older adults, it is recommended that a lower starting dosage be considered.

Administration Constraint Labeled Instruction
Timing Relative to Food 30 minutes before meals and at bedtime
Parenteral Procedure Must be injected over 1 to 2 minutes
Continuous Duration Limit Generally restricted to a maximum of 12 weeks
Organ Function Dose reduction mandatory for renal/hepatic impairment

Recent Clinical Evidence

Research Evidence / Overview of Studies for Metalon

Evidence for Use in Diabetic Gastroparesis

Research involving Metalon was studied in research exploring symptom patterns in diabetic gastroparesis primarily uses short-term randomized controlled trials (RCTs) and systematic reviews. Studies focused on adults with symptomatic diabetic gastroparesis. Research examined outcomes related to physical discomfort, such as patient-reported nausea, vomiting, and feelings of fullness or early satiety. Studies also monitored objective measures, specifically the rate at which the stomach empties, which is an outcome related to systemic or functional imbalance.

There is limited information for long-term outcomes in diabetic gastroparesis. Follow-up durations were limited, meaning that certainty remains low regarding the effects of using Metalon beyond the short-term study periods. Furthermore, data for certain groups remain insufficient. Study results also reflect the specific conditions under which they were conducted.

Evidence for Use in Acute Migraine Headache

Research involving Metalon for acute migraine largely consists of systematic reviews and meta-analyses that combine data from numerous clinical trials. Key outcomes describing episodic or acute changes were monitored, such as the achievement of a pain-free state and studies report how patient-reported pain intensity changed and associated nausea. The available research highlights changes measured during the study period, but the evidence is limited to the acute phase (typically up to 48 hours).

Evidence in Special Populations

Studies have examined Metalon's use in various populations, but data for certain groups remain insufficient. Older adults were observed in some studies. Data for children and pediatric patients remain limited. Consequently, certainty remains low regarding the long-term effects and functional outcomes in the general pediatric population.

The Research Landscape: Areas of Uncertainty

The body of evidence highlights what is known—and what is still uncertain. A consistent research limitation is that follow-up durations were limited, leaving the long-term effects and durability of any observed changes not fully established across all indications. Comparative evidence is lacking against all modern standard-of-care agents for some chronic conditions, and research is ongoing to fill these identified gaps.

Key Studies & References

  1. Metoclopramide: risk of neurological adverse effects - UK regulatory document
  2. The Safety of Metoclopramide in Children: A Systematic Review and Meta-Analysis

Frequently Asked Questions (FAQ)

Common questions about Metalon (FAQ)

Q: Does Metalon cause weight gain or weight loss?

A: Weight change is not listed as a common side effect in all official regulatory documents. However, some post-marketing or clinical reports have included cases of unexpected sudden weight gain and fluid retention. Changes in body weight are generally discussed with a healthcare provider.


Q: Can Metalon affect my ability to drive or operate machinery?

A: Yes, official product information advises caution. Because Metalon can cause side effects such as drowsiness (somnolence), dizziness, and involuntary movements, official guidance advises caution regarding driving or operating machinery, particularly when starting treatment, as the effects are individualized.


Q: Are there any specific foods I should avoid while on Metalon?

A: Official regulatory guidelines emphasize the importance of administration timing relative to food. Regulatory guidelines emphasize the importance of administering the medication relative to food, noting that it is typically taken before meals for best effect. No specific foods are restricted.


Q: Why do some people say they feel tired after taking Metalon?

A: Tiredness is a well-documented effect of this medication. Terms like somnolence (drowsiness) and asthenia (fatigue) are listed as very common or common side effects in official safety profiles. This is related to the drug's influence on the central nervous system.


Q: Is Metalon addictive or habit-forming?

A: Metalon (Metoclopramide) is not classified as a controlled substance by regulatory agencies in the United States and other international bodies. It is not generally considered to be addictive or habit-forming.


Q: Is it normal to have vivid dreams or sleep changes when using Metalon?

A: Difficulty with sleep, such as insomnia (difficulty falling or staying asleep), has been listed as an uncommon or infrequent side effect in some official sources. These sleep disturbances fall under the category of known central nervous system effects.


Q: Are there any supplements that interact badly with Metalon?

A: Official information provides specific warnings against combining Metalon with certain prescription drugs, such as Monoamine Oxidase Inhibitors (MAOIs). Official information generally recommends informing a healthcare provider of all herbal supplements and vitamins being taken due to the potential for unforeseen interactions.


Q: Can Metalon cause skin issues like a rash or increased sun sensitivity?

A: Yes, regulatory documents list certain skin reactions as adverse effects. Rash, hives (urticaria), and generalized allergic reactions are documented as rare side effects in the official safety profile.


Q: Does the effectiveness of Metalon decrease over time?

A: The official duration limit is a maximum of 12 weeks of continuous use. This restriction is primarily to mitigate the risk of serious, time-dependent neurological side effects, rather than due to confirmed loss of effectiveness (tolerance).


Q: Does Metalon affect mood or cause anxiety?

A: Yes, official prescribing information lists effects on mental health. Depression is documented as a common side effect. Less frequently, reactions such as anxiety, agitation, and confusion are also listed as potential adverse reactions.


Q: Is there a generic version of Metalon available?

A: Yes, the active ingredient in Metalon is Metoclopramide. This compound is widely available in generic versions, as well as multiple branded formulations, depending on location.


Q: Can Metalon be taken during pregnancy or while breastfeeding?

A: Official information states that use during pregnancy is conditional and involves a medical assessment to determine if the potential benefits are thought to outweigh the potential risks. Use during lactation (breastfeeding) is generally not recommended because the drug is known to pass into breast milk.


Q: What should I do if the side effects of Metalon are bothering me?

A: Official guidance emphasizes that patients should seek prompt medical attention if serious symptoms like new or unusual muscle movements, high fever, or confusion are noticed. Bothersome but non-serious side effects are typically addressed by a healthcare provider.


Q: Can Metalon cause changes to my appetite?

A: Yes. Loss of appetite is listed as a reported side effect in official patient information. This effect has been reported particularly in individuals taking the medicine for slow stomach emptying.


Q: Do I need any special monitoring or blood tests while on Metalon?

A: Patients with certain pre-existing conditions may require monitoring. Official prescribing information states that individuals with kidney or liver impairment may need a dose adjustment based on the results of function tests. Monitoring may also be considered for patients who metabolize the drug slowly (CYP2D6 poor metabolizers).


Q: Is it better to take Metalon in the morning or at night?

A: The official guidance specifies administration relative to meals (before each meal and at bedtime), indicating that timing with food intake is the primary factor, rather than a specific time of day.


Q: Are there any warning signs that an interaction with another drug is happening?

A: Warning signs depend on the interacting medicine. For example, interactions with other medications that cause central nervous system depression may lead to severe drowsiness, confusion, or dizziness. Uncontrolled muscle movements or a sudden spike in blood pressure are also signs of serious interactions.


Q: Can Metalon make me feel nauseous?

A: Yes, though the medicine is used to treat nausea and vomiting, nausea is paradoxically listed as a common side effect in the official adverse reactions section.


Q: Does the strength of Metalon affect the severity of side effects?

A: Yes. Official regulatory documents indicate that the risk of dose-related adverse reactions, such as Extrapyramidal Symptoms (EPS) (involuntary muscle movements), increases with higher doses of the medication.


Q: Has Metalon been approved in other countries?

A: Yes. The active ingredient, Metoclopramide, is approved for use and has official prescribing information available from regulatory bodies in many international territories, including the European Medicines Agency (EMA) and Health Canada.


Q: Does Metalon impact fertility?

A: Metalon can increase levels of the hormone prolactin, a condition called hyperprolactinemia. This hormonal change has been linked to effects such as menstrual irregularities in women and impotence in men, which could potentially impact the ability to conceive.


Q: Are there known cases of people having serious allergic reactions to Metalon?

A: Yes. While rare, the official safety profile includes reports of serious allergic reactions. These can include angioneurotic edema (swelling of the face, tongue, or throat) and breathing difficulty known as bronchospasm.


Q: What if I'm allergic to one of the inactive ingredients in Metalon?

A: Official contraindication information states that Metalon should not be used if a patient is allergic to the active medicine or to any of its ingredients, including the inactive components listed on the product label.


Q: How quickly should I expect to feel the effects of Metalon after starting it?

A: The official product information does not specify an exact time-to-onset (e.g., hours or days) for the relief of chronic symptoms. Patient response and symptom improvement are typically monitored by a healthcare provider during the first days or weeks of therapy.


Q: What happens if I accidentally miss a dose of Metalon?

A: Official labeling outlines the four-times-daily dosing schedule but does not provide specific instructions for a missed dose scenario. In situations involving a missed dose, the course of action is determined by the prescribing healthcare provider.


Q: Is Metalon the same as [Name of similar-sounding drug]? What's the difference?

A: Metalon is categorized as a Prokinetic Agent and an Antiemetic Agent. It is chemically known as a substituted benzamide. This classification distinguishes it pharmacologically from many other drugs used for similar conditions, which may belong to different chemical classes or work via different mechanisms.


Q: Does Metalon interact with common over-the-counter pain relievers like ibuprofen?

A: Official information mentions that Metalon can increase the rate of absorption of certain drugs from the stomach, such as Acetaminophen. While specific non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen may not be listed, it is generally recommended that a healthcare provider is informed of all over-the-counter pain relievers being used.


Q: What is the research evidence showing how effective Metalon is?

A: Official evidence summaries indicate that studies, primarily short-term randomized controlled trials (RCTs) and systematic reviews, support the use of Metalon for its main indications. Research has focused on outcomes such as patient-reported nausea, vomiting, and objective measures like the rate of stomach emptying.


Q: Does Metalon interfere with birth control pills?

A: Official labeling specifies interactions that alter drug absorption, such as decreasing Digoxin and increasing Cyclosporine levels. However, no direct, specific interaction warning is provided regarding oral contraceptive pills in the general warning sections.


Q: What is the maximum effective duration for Metalon treatment?

A: The maximum duration of continuous use is generally limited to 12 weeks. This limit is stated in the official safety information to mitigate the risk of developing serious neurological side effects, but it also implies that the benefit-to-risk ratio is best balanced in short-term use.

How should Metalon be stored and disposed of?

Official Storage and Disposal Requirements

Metalon (Metoclopramide) must be stored according to regulatory guidelines to maintain its stability and effectiveness.

Storage Conditions

Requirement Official Instruction
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Keep the medicine in its original, tightly closed container and protect from light and excessive moisture.
Prohibition Injectable solutions must not be frozen.
Child Safety Keep out of the sight and reach of children at all times.

Disposal Instructions

Unused or expired Metalon should be disposed of using methods specified by regulatory agencies. The preferred method is to use a drug take-back program or community collection event. If a take-back option is unavailable, the medicine should be mixed with an unappealing substance, sealed in a bag, and discarded in the household trash. The product should not be flushed down the toilet unless officially advised.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Metalon found in:

A-Z Index: